Phase 3Update

Tozorakimab (MEDI3506) (IL-33 Antibody)

Chronic Obstructive Pulmonary Disease

AZNAstrazeneca

Expected catalystTBA

Catalyst overview

Event details

Drug or asset: Tozorakimab (MEDI3506) (IL-33 Antibody)
Development stage: Phase 3
Event type: Update
Indication: Chronic Obstructive Pulmonary Disease

Research summary

What is being tracked?

This catalyst tracks a Phase 3 update for Tozorakimab (MEDI3506) (IL-33 Antibody) in Chronic Obstructive Pulmonary Disease. The expected timing is based on the latest available company guidance and may change.

Development notes

04/28/26:- OBERON, TITANIA and MIRANDA met endpoints; PROSPERO missed endpoint in COPD.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Tozorakimab (MEDI3506) (IL-33 Antibody)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

Enhertu

Enhertu/Trastuzumab Deruxtecan (DS-8201a) (HER2-Targeted ADC)

Baxdrostat

Imfinzi/Durvalumab + Bacillus Calmette-Guérin (MEDI4736) (PD-L1 Inhibitor)